Figure 3.
Resibufogenin (RB) inhibits canonical and noncanonical nuclear factor‐κB (NF‐κB) activity. A, Dual luciferase assay verified the NF‐κB activity in RB‐treated Panc‐1 and Aspc cells. B, C, Quantitative RT‐PCR and immunoblotting (IB) analysis of the mRNA and protein expression of c‐FLIPL and Bcl‐2 in Panc‐1 cells treated with 5 μmol/L RB for indicated the times. *P < .05, **P < .005; # P < .05, ## P < .005. D, E, Levels of phosphorylated (p‐)p65 and p65, p100, and p52 in Panc‐1 and Aspc cells treated with RB (5 μmol/L) for the indicated times, detected by IB. F, IB analysis of the nuclear (Nuc) and cytoplasmic (Cyt) fraction of p100 and p52 in Panc‐1 cells treated with 5 μmol/L RB for 24 hours